MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2136787
下载链接
链接失效反馈官方服务：
资源简介：
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma. Monoclonal antibodies, such as MORAb-004, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them
创建时间：
2013-11-15
